PMID- 31704853
OWN - NLM
STAT- MEDLINE
DCOM- 20191114
LR  - 20211204
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 39
IP  - 11
DP  - 2019 Nov
TI  - The mTOR Signaling Pathway Is Associated With the Prognosis of Malignant Pleural 
      Mesothelioma After Multimodality Therapy.
PG  - 6241-6247
LID - 10.21873/anticanres.13833 [doi]
AB  - BACKGROUND/AIM: We performed multimodality therapy comprising preoperative 
      chemotherapy, extrapleural pneumonectomy (EPP), and radiation therapy for 
      patients with malignant pleural mesothelioma (MPM). Although multimodality 
      therapy resulted in good prognosis, further improvement is required. Therefore, 
      herein, we analysed the prognostic factors using surgical specimens and searched 
      for suitable molecular targets to improve the prognosis after multidisciplinary 
      treatment. PATIENTS AND METHODS: Forty-six patients with MPM underwent 
      multimodality therapy. Paraffin-embedded surgical samples were used for 
      immunohistochemistry to evaluate the expression of phosphorylated (p-) AKT, 
      extracellular signal-regulated kinase (ERK), mammalian target of rapamycin 
      (mTOR), mitogen-activated protein kinase (MAPK), eukaryotic translation 
      initiation factor 4E-binding protein 1 (4E-BP1), and S6 ribosomal protein (S6RP). 
      RESULTS: On univariate and multivariate analyses, significant differences were 
      observed according to the histological type, pathological stage, and p-mTOR 
      expression rate. CONCLUSION: The prognosis of MPM is affected by p-mTOR 
      expression, suggesting that molecular-targeted treatment might be used during 
      multimodal therapy for MPM.
CI  - Copyright(c) 2019, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Kuroda, Ayumi
AU  - Kuroda A
AD  - Department of Thoracic Surgery, Hyogo Collage of Medicine, Nishinomiya, Japan.
FAU - Matsumoto, Seiji
AU  - Matsumoto S
AD  - Department of Thoracic Surgery, Hyogo Collage of Medicine, Nishinomiya, Japan 
      smatumo@hyo-med.ac.jp.
FAU - Fukuda, Akihiro
AU  - Fukuda A
AD  - Department of Thoracic Surgery, Hyogo Collage of Medicine, Nishinomiya, Japan.
AD  - Department of Thoracic Surgery, Saiseikai Noe Hospital, Osaka, Japan.
FAU - Nakamichi, Toru
AU  - Nakamichi T
AD  - Department of Thoracic Surgery, Hyogo Collage of Medicine, Nishinomiya, Japan.
FAU - Nakamura, Akifumi
AU  - Nakamura A
AD  - Department of Thoracic Surgery, Hyogo Collage of Medicine, Nishinomiya, Japan.
FAU - Hashimoto, Masaki
AU  - Hashimoto M
AD  - Department of Thoracic Surgery, Hyogo Collage of Medicine, Nishinomiya, Japan.
FAU - Takuwa, Teruhisa
AU  - Takuwa T
AD  - Department of Thoracic Surgery, Hyogo Collage of Medicine, Nishinomiya, Japan.
AD  - Department of Thoracic Surgery, Saiseikai Noe Hospital, Osaka, Japan.
FAU - Kondo, Nobuyuki
AU  - Kondo N
AD  - Department of Thoracic Surgery, Hyogo Collage of Medicine, Nishinomiya, Japan.
FAU - Tsujimura, Tohru
AU  - Tsujimura T
AD  - Department of Pathology, Hyogo Collage of Medicine, Nishinomiya, Japan.
FAU - Nakano, Takashi
AU  - Nakano T
AD  - Center for Respiratory Disease, Otemae Hospital, Osaka, Japan.
FAU - Hasegawa, Seiki
AU  - Hasegawa S
AD  - Department of Thoracic Surgery, Hyogo Collage of Medicine, Nishinomiya, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.24 (MAPK1 protein, human)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Biomarkers, Tumor/*analysis/metabolism
MH  - Cisplatin/administration & dosage
MH  - Combined Modality Therapy/methods
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Lung Neoplasms/*enzymology/mortality/therapy
MH  - Male
MH  - Mesothelioma/*enzymology/mortality/therapy
MH  - Mesothelioma, Malignant
MH  - Middle Aged
MH  - Mitogen-Activated Protein Kinase 1/*analysis/metabolism
MH  - Molecular Targeted Therapy
MH  - Pemetrexed/administration & dosage
MH  - Pleural Neoplasms/*enzymology/mortality/therapy
MH  - Pneumonectomy
MH  - Prognosis
MH  - Protein Serine-Threonine Kinases/analysis/metabolism
MH  - TOR Serine-Threonine Kinases/*analysis/metabolism
OTO - NOTNLM
OT  - extrapleural pneumonectomy
OT  - mTOR signal pathway
OT  - malignant pleural mesothelioma
EDAT- 2019/11/11 06:00
MHDA- 2019/11/15 06:00
CRDT- 2019/11/10 06:00
PHST- 2019/08/30 00:00 [received]
PHST- 2019/09/20 00:00 [revised]
PHST- 2019/09/25 00:00 [accepted]
PHST- 2019/11/10 06:00 [entrez]
PHST- 2019/11/11 06:00 [pubmed]
PHST- 2019/11/15 06:00 [medline]
AID - 39/11/6241 [pii]
AID - 10.21873/anticanres.13833 [doi]
PST - ppublish
SO  - Anticancer Res. 2019 Nov;39(11):6241-6247. doi: 10.21873/anticanres.13833.